News Releases
Dec 18, 2024
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium Read more
Dec 12, 2024
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 Read more
Dec 10, 2024
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer Read more
Nov 26, 2024
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference Read more
Nov 14, 2024
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer Read more
Nov 7, 2024
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update Read more
Nov 4, 2024
ALX Oncology Announces November Investor Conference Participation Read more
Nov 1, 2024
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 Read more
Sep 9, 2024
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference Read more
Sep 4, 2024
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi Read more